Rights and permissions
About this article
Cite this article
Imipenem/cilastatin preferred option for serious infection. Pharmacoecon. Outcomes News 207, 6 (1999). https://doi.org/10.1007/BF03274906
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03274906